SAN FRANCISCO, April 06, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in MiMedx Group, Inc. (NASDAQ:MDXG) of the April 25, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired securities of MiMedx between March 7, 2013 and February 21, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/MDXG
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On February 20, 2018, MiMedx postponed release of its fourth quarter and fiscal year 2017 financial results. Defendants explained “[t]he Audit Committee of MiMedx’s Board of Directors has engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company” and “Company executives are also reviewing, among other items, the accounting treatment of certain distributor contracts[.]”
This news drove the price of MiMedx shares down $5.72, or nearly 40%, to close at $8.75 on February 20, 2018.
Then, Reuters reported federal authorities are investigating whether MiMedx overcharged the government for its tissue-repair products and whether it improperly booked sales of products that hadn’t been ordered, a practice known as channel stuffing.
“We’re focused on Defendants’ previous denials of improper accounting that, if false, damaged investors and on whether MiMedx submitted false claims to the Federal government,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding MiMedx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000


Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Telegram Restored on Apple App Store After Temporary Removal
Apple Restores Telegram to App Store After Content Policy Violation
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Capital One Says AML Review Led to Closure of Trump Organization Accounts
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 



